The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
分析师眼中的再生元制药公司：14种不同观点
Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Regeneron Pharmaceuticals (NASDAQ:REGN) in the last three months.
在过去三个月中，有14位分析师公布了Regeneron Pharmicals（纳斯达克股票代码：REGN）的评级，提供了从看涨到看跌的不同视角。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Regeneron Pharmaceuticals, presenting an average target of $1111.86, a high estimate of $1229.00, and a low estimate of $925.00. This current average reflects an increase of 2.09% from the previous average price target of $1089.08.
在评估12个月目标股价时，分析师公布了对Regeneron Pharmicals的见解，将平均目标股价定为1111.86美元，最高估计为1229.00美元，低估值为925.00美元。目前的平均价格比之前的平均目标股价1089.08美元增长了2.09％。
Interpreting Analyst Ratings: A Closer Look
解读分析师评级：仔细观察
A comprehensive examination of...
对金融专...
登录免费看全文
登录/注册